Real Heart (HEART) - Total Assets
Based on the latest financial reports, Real Heart (HEART) holds total assets worth Skr87.94 Million SEK (≈ $9.46 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of Real Heart for net asset value and shareholders' equity analysis.
Real Heart - Total Assets Trend (2010–2024)
This chart illustrates how Real Heart's total assets have evolved over time, based on quarterly financial data.
Real Heart - Asset Composition Analysis
Current Asset Composition (December 2024)
Real Heart's total assets of Skr87.94 Million consist of 31.1% current assets and 68.9% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 28.5% |
| Accounts Receivable | Skr1.55 Million | 1.9% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr56.80 Million | 68.2% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2010–2024)
This chart illustrates how Real Heart's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Real Heart.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Real Heart's current assets represent 31.1% of total assets in 2024, a decrease from 46.8% in 2010.
- Cash Position: Cash and equivalents constituted 28.5% of total assets in 2024, down from 40.7% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 68.0% of total assets, an increase from 0.0% in 2010.
- Asset Diversification: The largest asset category is intangible assets at 68.2% of total assets.
Real Heart Competitors by Total Assets
Key competitors of Real Heart based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Demant A/S
CO:DEMANT
|
Denmark | Dkr39.07 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Beijing Wandong Medical Technology Co Ltd
SHG:600055
|
China | CN¥5.70 Billion |
|
Sinocare Inc
SHE:300298
|
China | CN¥6.25 Billion |
|
MODULIGHT OY EO 1
F:78W
|
Germany | €49.14 Million |
|
Diagnostic Medical Systems SA
PA:ALDMS
|
France | €57.17 Million |
|
Theradiag SA
PA:ALTHE
|
France | €11.55 Million |
|
Nova EYE Medical Ltd
AU:EYE
|
Australia | AU$23.67 Million |
Real Heart - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.96 | 1.53 | 9.06 |
| Quick Ratio | 2.96 | 1.53 | 9.06 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr19.82 Million | Skr9.07 Million | Skr27.60 Million |
Real Heart - Advanced Valuation Insights
This section examines the relationship between Real Heart's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.44 |
| Latest Market Cap to Assets Ratio | 0.11 |
| Asset Growth Rate (YoY) | -18.9% |
| Total Assets | Skr83.28 Million |
| Market Capitalization | $9.58 Million USD |
Valuation Analysis
Below Book Valuation: The market values Real Heart's assets below their book value (0.11x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Real Heart's assets decreased by 18.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Real Heart (2010–2024)
The table below shows the annual total assets of Real Heart from 2010 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr83.28 Million ≈ $8.96 Million |
-18.86% |
| 2023-12-31 | Skr102.64 Million ≈ $11.05 Million |
-14.34% |
| 2022-12-31 | Skr119.82 Million ≈ $12.89 Million |
+1.70% |
| 2021-12-31 | Skr117.82 Million ≈ $12.68 Million |
+50.96% |
| 2020-12-31 | Skr78.04 Million ≈ $8.40 Million |
+17.16% |
| 2019-12-31 | Skr66.61 Million ≈ $7.17 Million |
+142.90% |
| 2018-12-31 | Skr27.42 Million ≈ $2.95 Million |
-19.24% |
| 2017-12-31 | Skr33.96 Million ≈ $3.65 Million |
+68.05% |
| 2016-12-31 | Skr20.21 Million ≈ $2.17 Million |
+206.24% |
| 2015-12-31 | Skr6.60 Million ≈ $710.13K |
-21.02% |
| 2014-12-31 | Skr8.35 Million ≈ $899.08K |
+504.02% |
| 2013-12-31 | Skr1.38 Million ≈ $148.85K |
+11.79% |
| 2012-12-31 | Skr1.24 Million ≈ $133.16K |
+41.65% |
| 2011-12-31 | Skr873.53K ≈ $94.01K |
-10.06% |
| 2010-12-31 | Skr971.28K ≈ $104.53K |
-- |
About Real Heart
Scandinavian Real Heart AB (Publ) engages in the design and development of an artificial heart. The company develops Realheart TAH to treat advanced stage heart failure. It also develops RealVAD for pulsating left ventricle assist; PulsePump, a pulsating flow for heart and lung machines; and Sternal Prosthesis to fix the sternum after open-chest surgery. The company was founded in 1999 and is bas… Read more